Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an update.
On March 27, 2026, Biodexa Pharmaceuticals reported its audited preliminary results for the year ended December 31, 2025, highlighting a completed strategic shift from drug delivery into a focused therapeutics business targeting gastrointestinal cancers. The company’s pipeline, now fully clinical-stage, is anchored by eRapa in a registrational Phase 3 trial for Familial Adenomatous Polyposis and a Phase 2 study in bladder cancer, MTX240 in-licensed from Otsuka for GIST, and tolimidone in Phase 2a for type 1 diabetes, underscoring a more oncology- and GI-centric portfolio.
Operationally in 2025, Biodexa advanced multiple clinical milestones, including FDA and EMA progress for the Phase 3 Serenta trial of eRapa and initial patient enrollment in the U.S. and Europe, while an academic collaborator dosed the first patient in a Phase 2a tolimidone trial. The group also strengthened its intellectual property with a U.S. patent on oral rapamycin nanoparticle preparations and bolstered funding through partner CPRIT grant inflows and a $10 million financing, positioning the company to accelerate recruitment in its pivotal FAP trial, move MTX240 into Phase 1b/2a for GIST, and pursue partnering and non-dilutive capital options in 2026.
The most recent analyst rating on (BDRX) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
The score is pressured primarily by weak financial performance (zero 2024 revenue, persistent losses, and significant ongoing cash burn) and bearish technicals (price well below key moving averages with negative MACD). Valuation does not provide a clear offset due to negative earnings and no dividend yield data.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a Nasdaq-listed, clinical-stage biopharmaceutical company headquartered in Cardiff, U.K., focused on developing innovative therapies for gastrointestinal cancers and related indications. Its lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors, and tolimidone for type 1 diabetes, all positioned as clinical-stage assets aimed at oncology and metabolic disease markets.
The company has transitioned from a drug delivery specialist to a higher-value therapeutics developer, concentrating on gastrointestinal and oncology programs and relying on GMP-certified contract manufacturers rather than in-house production. Its business model centers on advancing assets through proof-of-concept and then out-licensing them to partners for late-stage development and commercialization, while retaining an option to commercialize eRapa in FAP due to substantial grant funding support.
Average Trading Volume: 255,839
Technical Sentiment Signal: Sell
Current Market Cap: $409.1K
For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.